» Authors » Robert A Bittner

Robert A Bittner

Explore the profile of Robert A Bittner including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 27
Citations 658
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Verdoux H, Bittner R, Hasan A, Qubad M, Wagner E, Lepetit A, et al.
Eur Psychiatry . 2025 Jan; 68(1):e17. PMID: 39788917
The European Clozapine Task Force is a group of psychiatrists and pharmacologists practicing in 18 countries under European Medicines Agency (EMA) regulation, who are deeply concerned about the underuse of...
2.
Qubad M, Dupont G, Hahn M, Martin S, Puntmann V, Nagel E, et al.
CNS Drugs . 2024 Jul; 38(9):671-696. PMID: 38951464
Clozapine-induced myocarditis (CIM) is among the most important adverse events limiting the use of clozapine as the most effective treatment for schizophrenia. CIM necessitates the immediate termination of clozapine, often...
3.
Barnes-Scheufler C, Rosler L, Schaum M, Schiweck C, Peters B, Mayer J, et al.
Psychol Med . 2024 Mar; 54(9):1965-1974. PMID: 38436135
Background: People with schizophrenia (PSZ) are impaired in attentional prioritization of non-salient but relevant stimuli over salient distractors during visual working memory (VWM) encoding. Conversely, guidance of top-down attention by...
4.
Bittner R, Reif A, Qubad M
Curr Opin Psychiatry . 2023 May; 36(4):327-336. PMID: 37222196
Purpose Of Review: Clozapine remains the gold standard for treatment-resistant schizophrenia (TRS). Although the evidence base for its wide-ranging, unique efficacy continues to expand, clozapine remains alarmingly underutilized in industrialized...
5.
Qubad M, Bittner R
Ther Adv Psychopharmacol . 2023 Mar; 13:20451253231158152. PMID: 36994117
Despite its enduring relevance as the single most effective and important evidence-based treatment for schizophrenia, underutilization of clozapine remains considerable. To a substantial degree, this is attributable to a reluctance...
6.
Brum M, Nieberler M, Kehrwald C, Knopf K, Brunkhorst-Kanaan N, Etyemez S, et al.
World J Biol Psychiatry . 2023 Jan; 24(7):564-577. PMID: 36648064
Objectives: Kynurenine, kynurenic and quinolinic acid are important metabolites in tryptophan metabolism. Due to an involvement in glutamatergic neurotransmission and immune response, previous studies have investigated this pathway in mental...
7.
Qubad M, Barnes-Scheufler C, Schaum M, Raspor E, Rosler L, Peters B, et al.
Sci Rep . 2022 Aug; 12(1):14310. PMID: 35995943
Studying the visual system with fMRI often requires using localizer paradigms to define regions of interest (ROIs). However, the considerable interindividual variability of the cerebral cortex represents a crucial confound...
8.
Freudenberg F, Althen H, Falk K, Bittner R, Reif A, Plichta M
Acta Neuropsychiatr . 2022 Aug; 34(6):344-353. PMID: 35959694
Objective: Sensorimotor gating is experimentally operationalized by the prepulse inhibition (PPI) of the startle response (SR). Previous studies suggest high test-retest reliability of PPI and potential correlation with working memory...
9.
Hettwer M, Lancaster T, Raspor E, Hahn P, Roth Mota N, Singer W, et al.
Schizophr Bull . 2022 Feb; 48(3):551-562. PMID: 35137221
Introduction: Illuminating neurobiological mechanisms underlying the protective effect of recently discovered common genetic resilience variants for schizophrenia is crucial for more effective prevention efforts. Current models implicate adaptive neuroplastic changes...
10.
McNeill R, Kehrwald C, Brum M, Knopf K, Brunkhorst-Kanaan N, Etyemez S, et al.
Brain Behav Immun . 2022 Jan; 101:275-283. PMID: 35041938
Nitric oxide (NO) signalling has been implicated in the pathogenesis of several mental illnesses; however, its specific contribution remains unclear. We investigated whether peripheral NO concentration is associated with specific...